Muxing Li
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Oncology top 10%
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Neuroendocrine Tumor Research Advances 5
- Surgery 6
- Cholangiocarcinoma and Gallbladder Cancer Studies 2
- Co-authors
- Yi Lv (8 shared papers)Jiwen Cheng (5 shared papers)Zhengwen Liu (3 shared papers)Wanli Wang (5 shared papers)Xu‐Feng Zhang (6 shared papers)Xuemin Liu (2 shared papers)Jian Dong (3 shared papers)Jianfei Zhang (1 shared paper)
- Journals
- Medicine (2 papers)HPB (2 papers)Clinical Science (1 paper)PLoS ONE (1 paper)Journal of Surgical Oncology (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Muxing Li
24 papers receiving 742 citations
Peers
Comparison fields: 5 of 71
- Hepatology 107
- Oncology 335
- Cancer Research 89
- Epidemiology 100
- Surgery 128
Countries citing papers authored by Muxing Li
This map shows the geographic impact of Muxing Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muxing Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muxing Li more than expected).
Fields of papers citing papers by Muxing Li
This network shows the impact of papers produced by Muxing Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muxing Li. The network helps show where Muxing Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Muxing Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 375 | |
| 2 | 2014 | 61 | |
| 3 | 2022 | 37 | |
| 4 | 2013 | 37 | |
| 5 | Diagnosis and treatment of hepatic tuberculosis: report of five cases and review of literature. | 2013 | 33 |
| 6 | 2018 | 28 | |
| 7 | 2013 | 27 | |
| 8 | 2014 | 23 | |
| 9 | 2021 | 21 | |
| 10 | 2013 | 19 | |
| 11 | 2021 | 15 | |
| 12 | 2016 | 15 | |
| 13 | 2022 | 10 | |
| 14 | 2022 | 8 | |
| 15 | 2017 | 8 | |
| 16 | 2013 | 7 | |
| 17 | 2016 | 7 | |
| 18 | 2022 | 6 | |
| 19 | 2022 | 5 | |
| 20 | Small-molecule exhibits anti-tumor activity by targeting the RNA m6A reader IGF2BP3 in ovarian cancer. | 2023 | 4 |
About Muxing Li
Muxing Li is a scholar working on Epidemiology, Surgery, Oncology, Hepatology and Cancer Research, having authored 26 papers that have together received 754 indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Cancer, Lipids, and Metabolism (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Lung Cancer Research Studies (2 papers), RNA modifications and cancer (2 papers) and Cancer-related molecular mechanisms research (2 papers). The work is most often cited by research in Hepatology (107 citations), Oncology (335 citations), Cancer Research (89 citations), Epidemiology (100 citations) and Surgery (128 citations). Muxing Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yi Lv, Jiwen Cheng, Zhengwen Liu, Wanli Wang, Xu‐Feng Zhang, Xuemin Liu, Jian Dong, Jianfei Zhang, Ying Zhu and Le Ma. Their work appears in journals such as Medicine, HPB, Clinical Science, PLoS ONE and Journal of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.